Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

BD introduces new insulin syringe for diabetes patients

Becton, Dickinson and Company (BD) has introduced a new insulin syringe, developed for diabetes people taking Eli Lilly manufactured Humulin R U-500 insulin.

Humulin R U-500 is concentrated insulin developed to treat high blood sugar in people with diabetes who need to inject more than 200 units of insulin per day.

The new BD U-500 insulin syringe has been designed to draw the correct dose of U-500 insulin by reducing steps.

Without a U-500 insulin syringe, diabetes patients and health care providers need to take additional steps to manually convert U-500 insulin doses to the appropriate dose or volume when using a traditional U-100 insulin syringe or tuberculin (volumetric) syringe.

According to BD, Humulin R U-500 insulin vials should not be prescribed without BD U-500 insulin syringes.

The new syringe features a 6 mm x 31-gauge syringe needle that will deliver insulin injections into the subcutaneous tissue while minimizing the risk of intramuscular injection. It includes clearly marked dosage labeling that helps to distinguish between other syringes.

Designed to dose up to 250 units, the new insulin syringe is a 0.5 mL syringe with clear and bold U-500 scale markings in five-unit increments.

In addition, the syringe package and components are color coded to adjust with the Humulin R U-500 insulin vial green concentration color marking and protective cap.

BD Diabetes Care global medical affairs vice president Dr Laurence Hirsch said: “Together BD and Lilly Diabetes have the unique opportunity to bring to market a solution that addresses the critical need of a very specific and important population of people with diabetes.

“This collaboration with Lilly exemplifies BD’s continued commitment to provide solutions for all people with diabetes, regardless of the population size, who need tailored treatment options in order to receive better management of their insulin delivery methods.”